ImmuPharma (LON:IMM) Shares Down 5.5% - Here's What Happened

Key Points

• ImmuPharma plc shares dropped by 5.5% to close at GBX 11.69 ($0.16), with trading volume at 4,997,618 shares, significantly lower than the average of 8,365,411 shares.
• The company posted a quarterly EPS of GBX (0.38) and is projected to have earnings of -339.00 for the current fiscal year, indicating continued financial challenges.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases and its lead product, Lupuzor™, targets Lupus and shows promise for other related conditions.

ImmuPharma plc (LON:IMM - Get Free Report) fell 5.5% during trading on Friday . The stock traded as low as GBX 11.20 ($0.15) and last traded at GBX 11.69 ($0.16). 4,997,618 shares were traded during mid-day trading, a decline of 40% from the average session volume of 8,365,411 shares. The stock had previously closed at GBX 12.38 ($0.16).

ImmuPharma Price Performance

The company's 50 day moving average price is GBX 8.75 and its 200 day moving average price is GBX 4.62. The firm has a market cap of £57.56 million, a PE ratio of -12.87 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Sell-side analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.